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In recent decades there has been an increased interest in polymeric nanoparticles as drug delivery systems 
thanks to their several advantages, such as continuous maintenance of drug levels in a therapeutically desirable 
range, and reduction of harmful side effects. These nano-colloids are generally made up of polyesters as long 
as they are able to easily degrade into the body. However, NP production is often a process that requires 
complex microfluidic devices. In addition, expensive purification steps are necessary to eliminate the unloaded 
drug and the high amount of organic solvent used in the NP production step. In the end, a lyophilization step is 
general adopted to assure a good shelf-life of the final product. All the above-mentioned steps hamper the cost-
effective use of a re-formulation of the same therapeutic agent and, in turn, reduce the availability of these 
treatments among the patient population. For this reason, in this work, a novel NP production protocol that 
consists only in the use of a syringe and a needle without the need of subsequent purification and freeze-drying 
steps has been developed. This has been possible by the optimization of the hydrophilic/lipophilic balance of 
block-copolymers that are able to directly self-assemble in water. The additional degree of freedom necessary 
for this optimization was introduced via the synthesis of these materials thorough the combination of the 
reversible addition-fragmentation chain transfer (RAFT) polymerization and the ring opening polymerization 
(ROP). The NPs has been used to formulate Trabectedin (ET-743), a widely adopted anticancer therapeutic 
known for its local adverse effect. The pharmacokinetic behavior, antitumor activity and toxicity of this novel NP-
based formulation has been compared to the commercially available formulation Yondelis®. NPs have shown 
the ability to retain the drug into circulation for a longer time in the blood stream compared to the free ET-743 
allowing to considerably reduce the local toxic effects. In addition, the shift of the NP preparation step from a 
specialist to the final user allows to avoid all the purifications and post-processing steps necessary to assure a 
good shelf-life of the product. In this way, a ET-743 formulation less toxic than the commercially available 
Yondelis® can be produced at a competitive price taking also into account that this expensive drug is not lost in 
any of the NP production steps here adopted. In order to prove the versatility of this novel technology, Paclitaxel 
(PTX), an anticancer therapeutic that it usually formulated with a toxic surfactant (Chremophor EL), have been 
also formulated into this NPs. In this way, a novel PTX formulation can be produced at a lower cost compared to 
the ones already approved and present into the market. In particular, it has shown the same advantage in 
reduction of the toxicity given by the elimination of the Chremophor EL (e.g in Abraxane® and Genexol®). 
 
